Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis
…, L Annemans, J Caro, CD Mullins, M Nuijten… - Value in …, 2007 - Wiley Online Library
Objectives: There is growing recognition that a comprehensive economic assessment of a
new health‐care intervention at the time of launch requires both a cost‐effectiveness analysis (…
new health‐care intervention at the time of launch requires both a cost‐effectiveness analysis (…
The economic costs of disease related malnutrition
…, JMM Meijers, RJG Halfens, MJC Nuijten - Clinical nutrition, 2013 - Elsevier
BACKGROUND & AIMS: Disease related malnutrition (under-nutrition caused by illness) is
a worldwide problem in all health care settings with potentially serious consequences on a …
a worldwide problem in all health care settings with potentially serious consequences on a …
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis
MJC Nuijten, W Wittenberg, M Lebmeier - Pharmacoeconomics, 2007 - Springer
Objective To assess the cost effectiveness of palivizumab (a preventative treatment against
severe respiratory syncytial virus [RSV] infection) in children at high risk of hospitalisation, ie …
severe respiratory syncytial virus [RSV] infection) in children at high risk of hospitalisation, ie …
The economic value of enteral medical nutrition in the management of disease-related malnutrition: a systematic review
… The duration of the ONS intervention in the analysis by Freijer and Nuijten 37 was 17 days,
following the guideline for the specific population. In the other evaluations, the duration of …
following the guideline for the specific population. In the other evaluations, the duration of …
[HTML][HTML] Importance of nondrug costs of intravenous antibiotic therapy
…, PM Engelfriet, K van Dillen, M van Veen, MJC Nuijten… - Critical Care, 2003 - Springer
Introduction Costs are one of the factors determining physicians' choice of medication to treat
patients in specific situations. However, usually only the drug acquisition costs are taken …
patients in specific situations. However, usually only the drug acquisition costs are taken …
Primary prevention of nephrolithiasis is cost‐effective for a national healthcare system
…, M Daudon, L Molinier, I Tack, MJC Nuijten - BJU …, 2012 - Wiley Online Library
… Mark JC Nuijten … Mark JC Nuijten … Yair Lotan, Michel Daudon, Laurent Molinier, Ivan Tack
and Mark JC Nuijten served as Consultants for Danone Inc. Inmaculada Buendia Jiménez and …
and Mark JC Nuijten served as Consultants for Danone Inc. Inmaculada Buendia Jiménez and …
Nutrition economics–characterising the economic and health impact of nutrition
…, MJ Poley, S Salminen, MJC Nuijten - British Journal of …, 2011 - cambridge.org
There is a new merging of health economics and nutrition disciplines to assess the impact of
diet on health and disease prevention and to characterise the health and economic aspects …
diet on health and disease prevention and to characterise the health and economic aspects …
[PDF][PDF] Pricing Zolgensma—The world's most expensive drug
M Nuijten - Journal of Market Access & Health Policy, 2022 - mdpi.com
… Mark Nuijten … [6] Nuijten M, Vis J. Economic comments on proposal for a novel cancer
drug pricing model. Nat Rev Clin Oncol. … Source of more in-depth considerations of …
drug pricing model. Nat Rev Clin Oncol. … Source of more in-depth considerations of …
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria
B Resch, C Sommer, MJC Nuijten… - The Pediatric …, 2012 - journals.lww.com
Objective: To assess the cost-effectiveness of palivizumab, a monoclonal antibody against
respiratory syncytial virus (RSV), in infants at high risk for severe RSV lower respiratory tract …
respiratory syncytial virus (RSV), in infants at high risk for severe RSV lower respiratory tract …
[HTML][HTML] Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with …
…, B Escudier, G Procopio, S Walzer, M Nuijten - British journal of …, 2010 - nature.com
Background: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to>
10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell …
10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell …